股本结构
单位：万股
| 公告日期 | 2026-10-09 | 2026-08-14 | 2026-08-14 | 2026-06-01 | 2026-05-26 | 2026-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 8721.92 | 8406.82 | 2492.93 | 2276.73 | 2276.73 | 1466.12 |
| 普通股本 | 8721.92 | 8406.82 | 2492.93 | 2276.73 | 2276.73 | 1466.12 |
| 优先股 | 未披露 | 未披露 | 500.00 | 500.00 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-10-07 | 2026-08-13 | 2026-06-30 | 2026-06-01 | 2026-05-26 | 2026-05-14 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-09 | 8721.92 | 未披露 | 定期报告 | 2026-10-07 |
| 2026-08-14 | 8406.82 | 未披露 | 定期报告 | 2026-08-13 |
| 2026-08-14 | 2492.93 | 500.00 |
更多>>
From March 31,2026 to June 30,2026
Ordinary shares issued for exercise of warrants
Preferred shares issued
Share-based expense
Ordinary shares issued for in-process research and development
|
2026-06-30 |
| 2026-06-01 | 2276.73 | 500.00 | 定期报告 | 2026-06-01 |
| 2026-05-26 | 2276.73 | 未披露 | 定期报告 | 2026-05-26 |
| 2026-05-15 | 1466.12 | 未披露 | 定期报告 | 2026-05-14 |
| 2026-05-15 | 1251.53 | 300.00 | 定期报告 | 2026-03-25 |
| 2026-03-25 | 1251.53 | 未披露 | 定期报告 | 2026-03-09 |
| 2026-03-31 | 978.01 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Sale of ordinary shares, warrants and prefunded warrants, exercise of prefunded warrants
Sale of ordinary shares
Share based expense
|
2025-12-31 |
| 2025-12-29 | 906.01 | 未披露 | 定期报告 | 2025-12-22 |
| 2025-11-26 | 858.39 | 未披露 | 定期报告 | 2025-11-20 |
| 2025-10-03 | 541.29 | 未披露 | 定期报告 | 2025-09-26 |
| 2025-07-30 | 457.79 | 未披露 | 定期报告 | 2025-07-25 |
| 2025-09-26 | 409.19 | 未披露 |
更多>>
From December 31, 2024 to June 30, 2025
Sale of ordinary shares and warrants and exercise of pre funded warrants
Share based expense
|
2025-06-30 |
| 2025-05-21 | 381.49 | 未披露 |
更多>>
Ordinary Units Offered 375,000 ordinary units by the company, Each ordinary unit consists of one ordinary share
|
2025-05-21 |
| 2025-06-05 | 343.99 | 未披露 | 定期报告 | 2025-05-05 |
| 2025-03-31 | 303.89 | 未披露 | 定期报告 | 2025-03-21 |
| 2025-03-31 | 231.94 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Sale of ordinary shares and warrants
Issuance of ordinary shares for conversion of debt
Issuance of ordinary shares for exercise of warrants
Share based expense
Reverse stock split adjustment
|
2024-12-31 |
| 2024-12-16 | 222.17 | 未披露 |
更多>>
Ordinary Units Offered 220,165 ordinary units by the company, Each ordinary unit consists of one ordinary share
|
2024-12-16 |
| 2024-12-16 | 200.14 | 未披露 | 定期报告 | 2024-12-13 |
| 2024-12-09 | 200.15 | 未披露 | 定期报告 | 2024-12-09 |
| 2024-11-29 | 200.00 | 未披露 |
更多>>
a 1-for-40 reverse stock split of its issued and outstanding shares
|
2024-12-03 |
| 2024-11-29 | 8010.00 | 未披露 | 定期报告 | 2024-11-29 |
| 2024-11-05 | 6404.10 | 未披露 | 定期报告 | 2024-11-05 |
| 2024-11-05 | 5814.05 | 未披露 | 定期报告 | 2024-10-16 |
| 2024-10-18 | 2558.66 | 未披露 | 定期报告 | 2024-06-30 |
| 2024-04-09 | 2188.66 | 未披露 | 定期报告 | 2024-03-26 |
| 2024-04-09 | 2116.55 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Share based expense
Issuance of ordinary shares for conversion of debt
Sale of ordinary shares
Issuance of ordinary shares for commitment fee
Issuance of ordinary shares for acquisition of intangible asset
Issuance of ordinary shares for exercise of warrants
|
2023-12-31 |
| 2023-11-14 | 2010.71 | 未披露 |
更多>>
Ordinary Shares Offered 3,359,655 Ordinary Shares by the company
|
2023-11-15 |
| 2023-09-26 | 1674.75 | 未披露 | 定期报告 | 2023-09-25 |
| 2023-11-14 | 1699.88 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-06-28 | 1524.75 | 未披露 | 定期报告 | 2023-06-28 |
| 2023-04-07 | 1482.66 | 未披露 | 定期报告 | 2023-04-04 |
| 2023-05-16 | 1482.66 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-04-07 | 1462.95 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Sale of ordinary shares and warrants
Issuance of ordinary shares for exercise of warrants
Share based expense
|
2022-12-31 |
| 2022-12-30 | 1449.30 | 未披露 | 定期报告 | 2022-12-27 |
| 2022-07-01 | 1448.30 | 未披露 | 定期报告 | 2022-06-21 |
| 2022-05-03 | 1396.05 | 未披露 | 定期报告 | 2022-04-15 |
| 2022-01-28 | 1351.00 | 未披露 |
更多>>
1.company entered into an underwriting agreement (the “Underwriting Agreement”) with Boustead Securities, LLC (the “Underwriter”) with respect to the issuance and sale in an underwritten public offering (the “Offering”) by company of an aggregate of 1,500,000 of ordinary shares (the “Ordinary Shares”) at a public offering price of $15.00 per Ordinary Share (the “Offering Price”).
|
2022-01-28 |
| 2022-05-03 | 1201.00 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issue of ordinary shares for conversion of debt
Recapitalization transaction
Sale of ordinary shares and warrants
|
2021-12-31 |
| 2021-11-12 | 1201.00 | 未披露 |
更多>>
1.Mainz Biomed N.V. today announced the underwriters have exercised their over-allotment option resulting in the issuance of an additional 300,000 shares.
|
2021-11-08 |
| 2021-11-12 | 1171.00 | 未披露 |
更多>>
1.Ordinary Shares Offered:1,000,000.
|
2021-11-05 |
From March 31,2026 to June 30,2026
Ordinary shares issued for exercise of warrants
Preferred shares issued
Share-based expense
Ordinary shares issued for in-process research and development
From December 31, 2024 to December 31, 2025
Sale of ordinary shares, warrants and prefunded warrants, exercise of prefunded warrants
Sale of ordinary shares
Share based expense
From December 31, 2024 to June 30, 2025
Sale of ordinary shares and warrants and exercise of pre funded warrants
Share based expense
Ordinary Units Offered 375,000 ordinary units by the company, Each ordinary unit consists of one ordinary share
From December 31, 2023 to December 31, 2024
Sale of ordinary shares and warrants
Issuance of ordinary shares for conversion of debt
Issuance of ordinary shares for exercise of warrants
Share based expense
Reverse stock split adjustment
Ordinary Units Offered 220,165 ordinary units by the company, Each ordinary unit consists of one ordinary share
a 1-for-40 reverse stock split of its issued and outstanding shares
From December 31, 2022 to December 31, 2023
Share based expense
Issuance of ordinary shares for conversion of debt
Sale of ordinary shares
Issuance of ordinary shares for commitment fee
Issuance of ordinary shares for acquisition of intangible asset
Issuance of ordinary shares for exercise of warrants
Ordinary Shares Offered 3,359,655 Ordinary Shares by the company
From December 31, 2021 to December 31, 2022
Sale of ordinary shares and warrants
Issuance of ordinary shares for exercise of warrants
Share based expense
1.company entered into an underwriting agreement (the “Underwriting Agreement”) with Boustead Securities, LLC (the “Underwriter”) with respect to the issuance and sale in an underwritten public offering (the “Offering”) by company of an aggregate of 1,500,000 of ordinary shares (the “Ordinary Shares”) at a public offering price of $15.00 per Ordinary Share (the “Offering Price”).
From December 31, 2020 to December 31, 2021
Issue of ordinary shares for conversion of debt
Recapitalization transaction
Sale of ordinary shares and warrants
1.Mainz Biomed N.V. today announced the underwriters have exercised their over-allotment option resulting in the issuance of an additional 300,000 shares.
1.Ordinary Shares Offered:1,000,000.